P1028: PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA
A. Kuykendall,
M. Kremyanskaya,
Y. Ginsburg,
N. Pemmaraju,
E. Ritchie,
J. Gotlib,
F. Valone,
S. Khanna,
S. Gupta,
R. Hoffman,
S. Verstovsek
Affiliations
A. Kuykendall
1 Hematology and Med Oncology, USF, Moffitt Cancer Center, Tampa
M. Kremyanskaya
2 Hematology, Mt. sinai, New york
Y. Ginsburg
2 Hematology, Mt. sinai, New york
N. Pemmaraju
3 Dept of Leukemia, M.D. Anderson, Houston, Tx
E. Ritchie
4 Hematology, Weill Cornell medical College, New york
J. Gotlib
5 Hematology, school of Medicine, Stanford, Palo Alto, Ca
F. Valone
6 Clinical Research and Development, Protagonist Therapeutics, Newark, United States of America
S. Khanna
6 Clinical Research and Development, Protagonist Therapeutics, Newark, United States of America
S. Gupta
6 Clinical Research and Development, Protagonist Therapeutics, Newark, United States of America